Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O60336

UPID:
MABP1_HUMAN

ALTERNATIVE NAMES:
JNK-binding protein 1

ALTERNATIVE UPACC:
O60336; A6NM93; A8K8P9; Q14CB5; Q14CD8; Q49AJ8; Q5W9G9

BACKGROUND:
The protein Mitogen-activated protein kinase-binding protein 1, alternatively known as JNK-binding protein 1, is integral to modulating cellular responses. It inhibits NOD2-induced NF-kappa-B signaling, IL8 secretion, and the antibacterial response, and participates in the JNK signaling pathway. This regulatory function underscores its importance in cellular homeostasis and response mechanisms.

THERAPEUTIC SIGNIFICANCE:
Linked to Nephronophthisis 20, a disease characterized by chronic kidney damage without extrarenal manifestations, Mitogen-activated protein kinase-binding protein 1's study offers a promising avenue for therapeutic intervention. Its pivotal role in disease mechanisms suggests potential for developing targeted treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.